Mechanism of action

The modifications distinguish semaglutide from the native intestinal hormone. Lau et al. (2015) described two amino-acid substitutions and a lipid-related modification at lysine 26. The lipid component and linker were selected to promote albumin binding while preserving receptor activity. The EMA describes GLP-1 receptor activation in terms of insulin release associated with nutrient intake and glucose regulation. These molecular and endocrine observations help explain the research rationale. They do not replace evidence on body-weight outcomes, adverse events or the behavior of a particular formulation, and an albumin-binding design should not be confused with unchanged GLP-1.

State of evidence

Wilding et al. examined a specified semaglutide preparation in STEP 1, a randomized double-blind trial involving 1,961 adults with overweight or obesity without diabetes. Both the semaglutide and placebo groups received lifestyle intervention. Over 68 weeks, the semaglutide group had greater weight reduction, while gastrointestinal adverse events were common and could lead to discontinuation. The study addresses that population and combination of conditions, rather than every possible population or preparation. The EMA's Ozempic assessment is a separate source of evidence on an authorized semaglutide-containing medicine for specified use in adults with type 2 diabetes. That authorization belongs to the evaluated medicinal product. It does not extend to an unidentified research sample, and it is not a general claim that all GLP-1-active compounds produce the same outcomes.

Questions about the research

How does semaglutide differ from native GLP-1?

It has amino-acid substitutions and a lipid-related modification, with design research examining receptor activity and albumin binding. The two molecules share a signaling context but are not structurally identical. Semaglutide should therefore be described as an analogue, rather than as unchanged GLP-1.

What question did STEP 1 investigate?

It compared a defined semaglutide preparation with placebo in adults with overweight or obesity without diabetes, alongside lifestyle intervention in both groups. Its weight-related findings and adverse-event observations must be interpreted within that design. They do not establish equivalent outcomes for another population or material.

Does an authorized semaglutide medicine validate a research sample?

No. A medicine assessment concerns a specified product, its manufacturing quality, formulation and evaluated conditions. A shared active-substance name does not supply that evidence for another sample. Chemical identity, preparation quality and clinical findings remain separate questions.

Sources

1. Lau et al., J Med Chem 2015DOI: 10.1021/acs.jmedchem.5b00726PMID: 26308095
2. Wilding et al., N Engl J Med 2021, STEP 1DOI: 10.1056/NEJMoa2032183PMID: 33567185
3. EMA, Ozempic European public assessment report
4. EMA, Ozempic current product information, pharmacokinetics section 5.2

Mechanism of action

The modifications distinguish semaglutide from the native intestinal hormone. Lau et al. (2015) described two amino-acid substitutions and a lipid-related modification at lysine 26. The lipid component and linker were selected to promote albumin binding while preserving receptor activity. The EMA describes GLP-1 receptor activation in terms of insulin release associated with nutrient intake and glucose regulation. These molecular and endocrine observations help explain the research rationale. They do not replace evidence on body-weight outcomes, adverse events or the behavior of a particular formulation, and an albumin-binding design should not be confused with unchanged GLP-1.

State of evidence

Wilding et al. examined a specified semaglutide preparation in STEP 1, a randomized double-blind trial involving 1,961 adults with overweight or obesity without diabetes. Both the semaglutide and placebo groups received lifestyle intervention. Over 68 weeks, the semaglutide group had greater weight reduction, while gastrointestinal adverse events were common and could lead to discontinuation. The study addresses that population and combination of conditions, rather than every possible population or preparation. The EMA's Ozempic assessment is a separate source of evidence on an authorized semaglutide-containing medicine for specified use in adults with type 2 diabetes. That authorization belongs to the evaluated medicinal product. It does not extend to an unidentified research sample, and it is not a general claim that all GLP-1-active compounds produce the same outcomes.

Questions about the research

How does semaglutide differ from native GLP-1?

It has amino-acid substitutions and a lipid-related modification, with design research examining receptor activity and albumin binding. The two molecules share a signaling context but are not structurally identical. Semaglutide should therefore be described as an analogue, rather than as unchanged GLP-1.

What question did STEP 1 investigate?

It compared a defined semaglutide preparation with placebo in adults with overweight or obesity without diabetes, alongside lifestyle intervention in both groups. Its weight-related findings and adverse-event observations must be interpreted within that design. They do not establish equivalent outcomes for another population or material.

Does an authorized semaglutide medicine validate a research sample?

No. A medicine assessment concerns a specified product, its manufacturing quality, formulation and evaluated conditions. A shared active-substance name does not supply that evidence for another sample. Chemical identity, preparation quality and clinical findings remain separate questions.

Sources

1. Lau et al., J Med Chem 2015DOI: 10.1021/acs.jmedchem.5b00726PMID: 26308095
2. Wilding et al., N Engl J Med 2021, STEP 1DOI: 10.1056/NEJMoa2032183PMID: 33567185
3. EMA, Ozempic European public assessment report
4. EMA, Ozempic current product information, pharmacokinetics section 5.2